Get the Stockscreener App
0.876
10.19%
0.081
Brainstorm Cell Therapeutics Inc stock is traded at $0.876, with a volume of 48,314.
It is up +10.19% in the last 24 hours and down -44.56% over the past month.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
See More
Previous Close:
$0.795
Open:
$0.81
24h Volume:
48,314
Relative Volume:
0.35
Market Cap:
$4.77M
Revenue:
-
Net Income/Loss:
$-16.63M
P/E Ratio:
-2.0372
EPS:
-0.43
Net Cash Flow:
$-21.84M
1W Performance:
-4.11%
1M Performance:
-44.56%
6M Performance:
-63.95%
1Y Performance:
-89.20%
1-Day Range:
$0.78
$0.914
1-Week Range:
$0.7233
$0.914
52-Week Range:
$0.7233
$10.05
Brainstorm Cell Therapeutics Inc Stock (BCLI) Company Profile
Name
Brainstorm Cell Therapeutics Inc
Sector
Industry
Phone
201-488-0460
Address
1325 AVENUE OF AMERICAS, NEW YORK, NY
Compare BCLI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCLI
Brainstorm Cell Therapeutics Inc
|
0.876 | 4.77M | 0 | -16.63M | -21.84M | -0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Brainstorm Cell Therapeutics Inc Stock (BCLI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-21 | Upgrade | Maxim Group | Hold → Buy |
| Nov-17-20 | Downgrade | Maxim Group | Buy → Hold |
| Dec-19-16 | Reiterated | Maxim Group | Buy |
| Dec-22-15 | Reiterated | Maxim Group | Buy |
Brainstorm Cell Therapeutics Inc Stock (BCLI) Latest News
Press Release Distribution & PR Platform - ACCESS Newswire
StockNews.com Initiates Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI) - Defense World
Brainstorm seeks FDA OK to launch NurOwn Phase 3b trial in ALS - ALS News Today
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Now Covered by Analysts at StockNews.com - Defense World
BrainStorm advances ALS therapy with FDA trial submission By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
BrainStorm advances ALS therapy with FDA trial submission - Investing.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALS - Nasdaq
Major FDA Progress: New Phase 3b Trial Brings NurOwn ALS Treatment Closer to Approval - Stock Titan
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Earns Hold Rating from Analysts at StockNews.com - Defense World
5 Best Stem Cell Companies to Invest In (April 2025) - Securities.io
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q4 2024 Earnings Call Transcript - Insider Monkey
BrainStorm Cell Therapeutics Reports 2024 Financial Results - TipRanks
BrainStorm Cell Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
Earnings call transcript: Brainstorm Cell Therapeutics Q4 2024 highlights cost-cutting - Investing.com Canada
Earnings call transcript: Brainstorm Cell Therapeutics Q4 2024 highlights cost-cutting By Investing.com - Investing.com South Africa
Brainstorm Cell Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
SHAREHOLDER ALERT: Potential Recovery for Brainstorm Cell Therapeutics Inc. (BCLI) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
BRAINSTORM CELL THERAPEUTICS INC. SEC 10-K Report - TradingView
SEC Form 10-K filed by Brainstorm Cell Therapeutics Inc. - Quantisnow
Brainstorm Cell Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits - Quantisnow
BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update - Nasdaq
INVESTOR ALERT: Potential Recovery for Brainstorm Cell Therapeutics Inc. (BCLI) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Brainstorm Cell Therapeutics (BCLI) to Release Earnings on Monday - Defense World
Brainstorm Cell Therapeutics Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Brainstorm Cell Therapeutics gains extension from Nasdaq - Investing.com
Brainstorm Cell Therapeutics gains extension from Nasdaq By Investing.com - Investing.com UK
BrainStorm Cell Therapeutics Granted Compliance Extension from N - GuruFocus.com
BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq - MarketScreener
BrainStorm Wins Critical Nasdaq Extension: New ALS Study and Strategic Plans Unveiled - Stock Titan
BrainStorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate Update - The Malaysian Reserve
Brainstorm Cell Therapeutics Appeals Nasdaq Delisting - MSN
Protara Therapeutics (NASDAQ:TARA) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) Financial Contrast - Defense World
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated at StockNews.com - Defense World
BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual Summit - Marketscreener.com
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Brainstorm Cell Therapeutics Inc.(BCLI) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
StockNews.com Begins Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI) - Defense World
Brainstorm Cell Therapeutics Inc. to Host Earnings Call - ACCESS Newswire
Brainstorm Cell Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Short Interest in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Expands By 21.3% - Defense World
Innovations in Stem Cell Therapy Market: Transforming - openPR
INVESTOR ALERT: Levi & Korsinsky Reminds Brainstorm Cell Therapeutics Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2024BCLI - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Brainstorm Cell Therapeutics Inc. (BCLI) Investigation - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineBCLI - ACCESS Newswire
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated by Analysts at StockNews.com - Defense World
INVESTOR ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineBCLI - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Reminds Brainstorm Cell Therapeutics Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2024BCLI - ACCESS Newswire
Brainstorm Cell Therapeutics Inc Stock (BCLI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Brainstorm Cell Therapeutics Inc Stock (BCLI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lebovits Chaim | President & CEO |
Sep 30 '24 |
Buy |
0.23 |
22,000 |
5,016 |
1,186,865 |
| Dagher Ibrahim B. | Chief Medical Officer |
Jul 19 '24 |
Sale |
0.35 |
63,000 |
22,069 |
0 |
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):